BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 20378303)

  • 1. [Targeted therapies in hepatocellular carcinoma].
    Bouattour M; Marijon H; Dreyer C; Faivre S; Raymond E
    Presse Med; 2010; 39(7-8):753-64. PubMed ID: 20378303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing the efficacy of sunitinib with sorafenib in xenograft models of human hepatocellular carcinoma: mechanistic explanation.
    Huynh H; Choo SP; Toh HC; Tai WM; Chung AY; Chow PK; Ong R; Soo KC
    Curr Cancer Drug Targets; 2011 Oct; 11(8):944-53. PubMed ID: 21834756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma.
    Zhu AX
    Cancer; 2008 Jan; 112(2):250-9. PubMed ID: 18041064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
    Cheng AL; Kang YK; Chen Z; Tsao CJ; Qin S; Kim JS; Luo R; Feng J; Ye S; Yang TS; Xu J; Sun Y; Liang H; Liu J; Wang J; Tak WY; Pan H; Burock K; Zou J; Voliotis D; Guan Z
    Lancet Oncol; 2009 Jan; 10(1):25-34. PubMed ID: 19095497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular therapy for the treatment of hepatocellular carcinoma.
    Greten TF; Korangy F; Manns MP; Malek NP
    Br J Cancer; 2009 Jan; 100(1):19-23. PubMed ID: 19018262
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of hepatocellular carcinoma: beyond sorafenib.
    Chan SL; Mok T; Ma BB
    Curr Oncol Rep; 2012 Jun; 14(3):257-66. PubMed ID: 22434314
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Developing better treatments in hepatocellular carcinoma.
    Duffy A; Greten T
    Expert Rev Gastroenterol Hepatol; 2010 Oct; 4(5):551-60. PubMed ID: 20932140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the indication for sorafenib in hepatocellular carcinoma? A clinical challenge.
    Kim R; Byrne MT; Tan A; Aucejo F
    Oncology (Williston Park); 2011 Mar; 25(3):283-91, 295. PubMed ID: 21548473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sequential therapy with sunitinib and sorafenib in metastatic hepatocellular carcinoma.
    Ahn HK; Lee S; Sun JM; Lee J; Park SH; Park JO; Park YS; Kang WK; Lim HY
    Invest New Drugs; 2012 Aug; 30(4):1768-72. PubMed ID: 21720741
    [No Abstract]   [Full Text] [Related]  

  • 10. Sorafenib: where do we go from here?
    Siegel AB; Olsen SK; Magun A; Brown RS
    Hepatology; 2010 Jul; 52(1):360-9. PubMed ID: 20578152
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib for the treatment of advanced hepatocellular carcinoma.
    Connock M; Round J; Bayliss S; Tubeuf S; Greenheld W; Moore D
    Health Technol Assess; 2010 May; 14 Suppl 1():17-21. PubMed ID: 20507799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of systemic therapy of advanced hepatocellular carcinoma.
    Yau T; Chan P; Epstein R; Poon RT
    World J Gastroenterol; 2008 Nov; 14(42):6437-41. PubMed ID: 19030192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib in hepatocellular carcinoma.
    Josephs DH; Ross PJ
    Br J Hosp Med (Lond); 2010 Aug; 71(8):451-6. PubMed ID: 20852487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systemic therapy of hepatocellular carcinoma: current and promising.
    Kalyan A; Nimeiri H; Kulik L
    Clin Liver Dis; 2015 May; 19(2):421-32. PubMed ID: 25921671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sunitinib in patients with advanced hepatocellular carcinoma after progression under sorafenib treatment.
    Wörns MA; Schuchmann M; Düber C; Otto G; Galle PR; Weinmann A
    Oncology; 2010; 79(1-2):85-92. PubMed ID: 21071995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib in advanced hepatocellular carcinoma.
    Palmer DH
    N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065750
    [No Abstract]   [Full Text] [Related]  

  • 17. Sorafenib in advanced hepatocellular carcinoma.
    Copur MS
    N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065701
    [No Abstract]   [Full Text] [Related]  

  • 18. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
    Yau T; Pang R; Chan P; Poon RT
    Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced hepatocellular carcinoma. Review of targeted molecular drugs.
    Alves RC; Alves D; Guz B; Matos C; Viana M; Harriz M; Terrabuio D; Kondo M; Gampel O; Polletti P
    Ann Hepatol; 2011; 10(1):21-7. PubMed ID: 21301005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib: in hepatocellular carcinoma.
    Simpson D; Keating GM
    Drugs; 2008; 68(2):251-8. PubMed ID: 18197728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.